<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096820</url>
  </required_header>
  <id_info>
    <org_study_id>6026618</org_study_id>
    <nct_id>NCT04096820</nct_id>
  </id_info>
  <brief_title>Uromune in Treating Recurrent Urinary Tract Infections in Women</brief_title>
  <official_title>Protocol 19-01: Canadian, Single Centre, Pilot, Open Label Study to Evaluate the Efficacy and Safety of the Bacterial Vaccine Uromune in Treating Recurrent Urinary Tract Infections in Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effectiveness and safety of the vaccine Uromune in Canadian women with&#xD;
      recurrent urinary tract infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposal is for a real life clinical practice study in which female participants with a&#xD;
      predefined history of recurrent UTIs in the previous year will be treated with 3 months of&#xD;
      oral vaccine with a further 9 months of follow-up. The primary outcome will be no UTI in the&#xD;
      12 months following initiation of the vaccine (definition of a responder). A clinically&#xD;
      significant and important outcome will be defined as a responder rate of 50% (50% of&#xD;
      participants who had at least 3 UTIs in the previous year reporting no UTIs after therapy&#xD;
      initiated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 6, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Responder</measure>
    <time_frame>12 months</time_frame>
    <description>Participant considered complete responder if no UTI requiring antibiotics reported 12 months since initiating therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder Rate</measure>
    <time_frame>12 months</time_frame>
    <description>The number of UTI in individual participants requiring antibiotics in the 12 months after starting therapy will be compared to the number of UTIs requiring antibiotics before therapy is initiated (number over previous 12 months or 2 X the number over the preceding 6 months).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Recurrent Uti</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uromune will be taken by the participant for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Uromune</intervention_name>
    <description>2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.</description>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Can provide written consent and willingness to comply with all aspects of study&#xD;
             treatment and study requirements.&#xD;
&#xD;
          -  Individuals who have had at least 3 episodes of a UTI in the past 12 months or 2 UTI&#xD;
             episodes in the past 6 months. At least one of the UTI episodes must be associated&#xD;
             with a positive urine culture with a traditional uropathogen including Escherichia&#xD;
             coli, Proteus spp. Staphyloccous sp. Enterococcus sp. Klebsiella sp. or Pseudomonas&#xD;
             aeruginosa.&#xD;
&#xD;
          -  Post-menopausal for a minimum of 1 year or negative pregnancy test if participant is&#xD;
             of child bearing potential and agreement to acceptable contraceptive use from&#xD;
             Screening Visit 1 to final follow up visit if participant is sexually active.&#xD;
             Medically acceptable methods of contraception include hormonal contraception (i.e.&#xD;
             estrogen, and/or progesterone or preparations that contain a combination of these&#xD;
             hormones), non-hormonal intrauterine device or double barrier method (i.e. condom with&#xD;
             foam or vaginal spermicidal suppository, or diaphragm with spermicide) or vasectomy of&#xD;
             sole sexual partner. Complete abstinence alone can be used as a method of&#xD;
             contraception.&#xD;
&#xD;
          -  Free of a urinary tract infection at the time of trial inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of bladder tumours including uterine, cervical, vaginal or urethral cancer.&#xD;
&#xD;
          -  Worrisome post-voiding residual (investigator's discretion).&#xD;
&#xD;
          -  Infection related to urinary lithiasis.&#xD;
&#xD;
          -  Any immunological disease requiring active therapy.&#xD;
&#xD;
          -  Currently receiving Immunotherapy.&#xD;
&#xD;
          -  Taking any prophylactic antibiotics at screening. Any prophylactic antibiotics must be&#xD;
             stopped the day of the screening visit.&#xD;
&#xD;
          -  Any known intolerance to the ingredients of the UromuneÂ® Immunotherapy.&#xD;
&#xD;
          -  Have any other condition or disease which, in the opinion of the investigator, could&#xD;
             compromise participant safety or interfere with the participant's participation in the&#xD;
             study or in the evaluation of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Curtis Nickel, MD, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Urology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Advanced Urological Research</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. J. Curtis Nickel</investigator_full_name>
    <investigator_title>Professor or Urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT04096820/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT04096820/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

